Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteriaGeoff D.E. Cuvelier, Kirk R. Schultz, Kimberly A. Kasow et al.|Blood|2019Cited by 89
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studiesKirk R. Schultz, Geoff D.E. Cuvelier, Amina Kariminia et al.|Blood|2020Cited by 67
KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trialMichael A. Pulsipher, Hisham Abdel‐Azim, Kwang Woo Ahn et al.|Blood|2022Cited by 30
Recent Thymic Emigrants and Tregs Expressing CD31 and CD45RA Are Decreased at Day 100 and Prognostic for Chronic GvHD in Children: Results From the Applied Biomarkers of Late Effects (ABLE)/Pediatric Blood and Marrow Transplant Consortium 1202 StudyGeoff D.E. Cuvelier, Kirk R. Schultz, Eneida R. Nemecek et al.|Transplantation and Cellular Therapy|2018Cited by 0
High OS, PFS and EFS with Low Rates of Rejection and GVHD after KIR-Favorable abCD3/CD19 Depleted Haploidentical HCT in Children with ALL/AML/MDS: Primary Analysis of the Pediatric Transplantation and Cellular Therapy Consortium ONC1401 TrialHisham Abdel‐Azim, Mike A. Pulsipher, Christopher C. Dvorak et al.|Transplantation and Cellular Therapy|2021Cited by 0